Disease
Multiple Myeloma
A plasma-cell hematologic malignancy, treated with induction, autologous transplant where eligible, and continuous/maintenance therapy across proteasome inhibitor, IMiD, anti-CD38, and (increasingly) bispecific/CAR-T drug classes.
Coverage in progress. AssetMemo has not yet run its full census for Autologous Stem Cell Conditioning in Multiple Myeloma, so the assets listed for it are not complete.
Combined attributable cost
$13.7B+
Drug spend
$6.7B+
49% of total cost is drugs
Sum of 2 indications below.